Compare BIOA & ZSQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIOA | ZSQR |
|---|---|---|
| Founded | 2015 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 204.6M |
| IPO Year | 2024 | 2020 |
| Metric | BIOA | ZSQR |
|---|---|---|
| Price | $5.47 | $3.92 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $32.56 | N/A |
| AVG Volume (30 Days) | ★ 830.4K | 445.4K |
| Earning Date | 11-05-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.21 | 50.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,995,000.00 | $1,363,045.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $97.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.81 | $2.11 |
| 52 Week High | $25.96 | $16.62 |
| Indicator | BIOA | ZSQR |
|---|---|---|
| Relative Strength Index (RSI) | 31.30 | 47.08 |
| Support Level | N/A | $2.81 |
| Resistance Level | $8.53 | $4.69 |
| Average True Range (ATR) | 0.37 | 0.66 |
| MACD | 0.10 | -0.12 |
| Stochastic Oscillator | 35.92 | 16.95 |
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.